Skip to main content

Insulin glargine_Lixisenatide(1)

10-04-2021 | EASD 2021 | Conference coverage | News

SoliMix trial supports iGlarLixi for type 2 diabetes

Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.

04-23-2021 | Insulin | News

Pragmatic trial challenges ‘dogma’ of basal–bolus insulin for advanced type 2 diabetes

Combining a GLP-1 receptor agonist or SGLT2 inhibitor with basal insulin allows people with type 2 diabetes on a basal–bolus regimen to drop the prandial insulin, shows the pragmatic BEYOND trial.